SOPHiA GENETICS（SOPH）株式概要
SOPHiA GENETICS SAは、ヘルスケア分野におけるクラウドネイティブなソフトウェア・テクノロジー企業として事業を展開している。 詳細
SOPH Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
SOPHiA GENETICS SA 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$8.28 |
| 52週高値 | US$8.31 |
| 52週安値 | US$3.10 |
| ベータ | 0.92 |
| 1ヶ月の変化 | 30.81% |
| 3ヶ月変化 | 63.96% |
| 1年変化 | 131.28% |
| 3年間の変化 | 249.37% |
| 5年間の変化 | -54.38% |
| IPOからの変化 | -50.60% |
最新ニュース
Recent updates
ナラティブ更新 • Aug 18
SOPH: Astrazeneca Partnerships And AI Platform Will Drive Future Oncology Opportunity
Analysts have lifted the SOPHiA GENETICS analyst price target from $12 to $14, citing recent Street research that highlights stronger Q2 results, a raised outlook, major AstraZeneca and companion diagnostics partnerships, growing U.S. adoption, and recurring, usage based revenue streams across clinical and biopharma markets as key supports for this updated view. Analyst Commentary Bullish analysts see SOPHiA GENETICS as a company that is executing on its plan, with recent research pointing to what they view as strong Q2 results, a raised outlook, and expanding commercial traction.ナラティブ更新 • Aug 04
SOPH: AI Multimodal Data Platform Will Drive Future Oncology Opportunity
Analysts have raised their price target on SOPHiA GENETICS from $9 to $12, citing the company's AI-driven use of multimodal genomic and clinical data, its recurring usage-based revenue model across clinical and biopharma customers, and its exposure to an estimated $40 billion market. What’s in the News for SOPHiA GENETICS SOPHiA GENETICS filed and then completed a follow on equity offering of common stock, raising US$49.9985 million through 10,526,000 shares priced at US$4.75 per share with a US$0.285 discount per share.
ナラティブ更新 • Jul 21
SOPH: AI Usage Model And NHS Rollout Will Drive Future Upside
Analysts have raised their price target on SOPHiA GENETICS stock to $12, citing the company’s AI-driven, usage-based revenue model across clinical and biopharma customers, as well as its exposure to an estimated $40 billion addressable market, as key factors supporting the updated valuation and fair value assumptions. What’s in the News for SOPHiA GENETICS SOPHiA GENETICS completed a follow on equity offering of 10,526,000 common shares at US$4.75 per share, raising approximately US$49.9985 million.Seeking Alpha • Jun 18
SOPHiA Genetics: Strong Growth Meets A Critical Execution Phase
Summary SOPHiA GENETICS is approaching an inflection point in precision medicine, leveraging AI-driven genomic analysis as sequencing costs decline and data complexity rises. SOPH's platform benefits from a self-reinforcing data flywheel, with 2.5 million genomic profiles and 537 institutions using SOPHiA DDM across 75 countries. Revenue grew 22% year-over-year to $21.7M in 1Q26, with 117% net dollar retention and adjusted gross margin of 75.4%, but profitability remains a key watchpoint. Management targets adjusted EBITDA breakeven by end-2026 and profitability in 2027, supported by cost discipline, new high-value applications, and expanding customer adoption. Read the full article on Seeking Alpha
ナラティブ更新 • Jun 15
SOPH: New Partnerships And Ai Collaboration Will Support Future Precision Oncology
Analysts have increased their price target on SOPHiA GENETICS by $1, reflecting updated views on fair value, discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News SOPHiA GENETICS signed a Memorandum of Understanding with Memorial Sloan Kettering Cancer Center to form a joint venture that aims to combine Memorial Sloan Kettering Cancer Center clinical data with the SOPHiA DDM Ai platform for multimodal precision oncology research and deployment.ナラティブ更新 • Jun 01
SOPH: NHS Liquid Biopsy Rollout Will Support Future Upside Potential
Analysts have lifted their price target on SOPHiA GENETICS by $1, citing updated models that reflect a lower discount rate, adjusted revenue growth and profit margin assumptions, and a revised future P/E estimate. What's in the News SOPHiA GENETICS partnered with Synnovis, a leading pathology provider in England, to roll out liquid biopsy testing for lung and breast cancer patients across the U.K. under NHS England's blood test first program, using the MSK-ACCESS® test powered by SOPHiA DDM™.ナラティブ更新 • May 15
SOPH: New NHS Partnerships Will Support Future Precision Oncology Adoption
Analysts recently lifted their price target on SOPHiA GENETICS by $1, citing updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E that together support a slightly higher valuation framework for the stock. Analyst Commentary Recent research has framed the updated price target as a fine tuning of prior assumptions rather than a major shift in conviction.ナラティブ更新 • Apr 24
SOPH: Higher Future P/E Assumptions Will Support Upside Potential
Analysts lifted their price target on SOPHiA GENETICS by about $0.33 to $8.00, citing updated assumptions around fair value, discount rate, and future P/E that reflect recent research from multiple firms. Analyst Commentary Recent Street research has pointed to updated assumptions around fair value, the discount rate, and forward P/E as the main drivers behind the refreshed $8.00 price target on SOPHiA GENETICS.ナラティブ更新 • Apr 09
SOPH: New U.S. Health System Partnerships Will Drive Future Upside
Analysts have raised their price target on SOPHiA GENETICS by $1, reflecting updated views on the company’s discount rate, revenue growth outlook, profit margin assumptions, and future P/E as highlighted in recent Street research. Analyst Commentary Recent Street research around SOPHiA GENETICS points to a more cautious tone, even as price targets are adjusted to reflect updated assumptions around discount rates, revenue growth, profit margins, and future P/E multiples.ナラティブ更新 • Mar 26
SOPH: Higher Future P/E And New U.S. Partnerships Will Support Upside
Analysts raised their price target on SOPHiA GENETICS by $1, reflecting updated views on factors such as revenue growth expectations, discount rate assumptions, profit margin outlook, and a recalibrated future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as better aligning the stock with updated expectations for revenue growth, which they view as supportive of a richer valuation multiple.ナラティブ更新 • Mar 11
SOPH: New US Health System Deals Will Support Future Upside
Analysts lifted their fair value estimate for SOPHiA GENETICS by $1.00 to $7.00, citing updated assumptions for growth, profitability, and future P/E that align with the recent $1 upward move in the Street price target. Analyst Commentary While the latest fair value move to $7.00 lines up with the recent Street price target adjustment, not everyone is leaning positive.ナラティブ更新 • Feb 25
SOPH: Higher Implied P/E And New Partnerships Will Support Future Platform Adoption
Analysts have raised their price target on SOPHiA GENETICS by $1, citing updated assumptions on discount rate and long term profitability that result in a slightly higher implied future P/E of 79.26x. Analyst Commentary Analysts raising the price target by $1 are essentially saying that, based on their updated models, the shares now justify a slightly richer valuation, reflected in the implied future P/E of 79.26x.ナラティブ更新 • Feb 10
SOPH: Oncology Collaboration And New Leadership Will Support Future Platform Adoption
Analysts have nudged their price target on SOPHiA GENETICS higher by about US$1, reflecting updated views on the company that are consistent with recent Street research commentary. Analyst Commentary Bullish Takeaways Bullish analysts connect the roughly US$1 price target adjustment to refreshed expectations on how SOPHiA GENETICS can execute on its roadmap.ナラティブ更新 • Jan 27
SOPH: Higher Price Work Will Highlight Expanding Oncology Collaborations
Analysts have increased their price target on SOPHiA GENETICS by US$1, citing updated assumptions around fair value, discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts lifting their fair value assumptions by US$1 are essentially fine tuning how they see SOPHiA GENETICS balancing growth potential, execution risk, and valuation multiples such as P/E over time.分析記事 • Sep 30
Market Participants Recognise SOPHiA GENETICS SA's (NASDAQ:SOPH) Revenues Pushing Shares 28% Higher
SOPHiA GENETICS SA ( NASDAQ:SOPH ) shares have continued their recent momentum with a 28% gain in the last month alone...分析記事 • Aug 08
Analysts Are Updating Their SOPHiA GENETICS SA (NASDAQ:SOPH) Estimates After Its Second-Quarter Results
NasdaqGS:SOPH 1 Year Share Price vs Fair Value Explore SOPHiA GENETICS's Fair Values from the Community and select...ナラティブ更新 • Aug 06
Precision Medicine Advances Will Transform Global Healthcare Analytics
SOPHiA GENETICS' consensus price target has been reduced to $6.75, primarily reflecting lowered revenue growth expectations despite a modest improvement in net profit margin. What's in the News SOPHiA GENETICS reiterated its full-year 2025 revenue guidance of $72 million to $76 million.分析記事 • Jul 10
Revenues Tell The Story For SOPHiA GENETICS SA (NASDAQ:SOPH) As Its Stock Soars 29%
SOPHiA GENETICS SA ( NASDAQ:SOPH ) shareholders have had their patience rewarded with a 29% share price jump in the...
新しいナラティブ • Apr 02
Expedited Implementation And New US Signings Will Boost Future Impact
Expansion in the U.S. market and major new customer acquisitions like Mount Sinai are poised to significantly boost revenue and market share.分析記事 • Mar 20
With A 25% Price Drop For SOPHiA GENETICS SA (NASDAQ:SOPH) You'll Still Get What You Pay For
SOPHiA GENETICS SA ( NASDAQ:SOPH ) shareholders won't be pleased to see that the share price has had a very rough...分析記事 • Jan 10
Shareholders Should Be Pleased With SOPHiA GENETICS SA's (NASDAQ:SOPH) Price
When close to half the companies in the Healthcare Services industry in the United States have price-to-sales ratios...分析記事 • Oct 03
Is SOPHiA GENETICS (NASDAQ:SOPH) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Aug 09
SOPHiA GENETICS SA (NASDAQ:SOPH) Just Reported, And Analysts Assigned A US$6.00 Price Target
Shareholders in SOPHiA GENETICS SA ( NASDAQ:SOPH ) had a terrible week, as shares crashed 25% to US$3.36 in the week...分析記事 • Aug 08
Investors Still Waiting For A Pull Back In SOPHiA GENETICS SA (NASDAQ:SOPH)
When you see that almost half of the companies in the Healthcare Services industry in the United States have...株主還元
| SOPH | US Healthcare Services | US 市場 | |
|---|---|---|---|
| 7D | 9.4% | 2.8% | -0.3% |
| 1Y | 131.3% | -22.4% | 19.9% |
業界別リターン: SOPH過去 1 年間で-22.4 % の収益を上げたUS Healthcare Services業界を上回りました。
リターン対市場: SOPH過去 1 年間で19.9 % の収益を上げたUS市場を上回りました。
価格変動
| SOPH volatility | |
|---|---|
| SOPH Average Weekly Movement | 10.2% |
| Healthcare Services Industry Average Movement | 10.0% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
安定した株価: SOPH 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: SOPHの 週次ボラティリティ ( 10% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2011 | 415 | Ross Muken | www.sophiagenetics.com |
SOPHiA GENETICS SAは、ヘルスケア分野におけるクラウドネイティブのソフトウェアテクノロジー企業として事業を展開しています。同社は、マルチモーダルデータセットや診断モダリティからデータを分析し、知見を導き出すためのクラウドネイティブソフトウェアプラットフォーム「SOPHiA DDMプラットフォーム」を提供しています。 同社の「SOPHiA DDM」プラットフォームおよび関連するソリューション、アプリケーション、製品、サービスは、スイス、フランス、イタリア、その他の欧州諸国、北米、米国、ラテンアメリカ、アジア太平洋地域において、自社の営業部隊に加え、販売代理店や業界パートナーを通じて、病院、検査機関、バイオ医薬品企業に利用されています。 同社は、英国の患者に血液ベースのがん検査を提供するためSynnovis社と提携しており、また、アストラゼネカ社とは、精密腫瘍学治療を支援する2つのコンパニオン診断（CDx）の開発、検証、導入に向けた協業を行っています。同社は2011年に設立され、スイスのロールに本社を置いています。
SOPHiA GENETICS SA 基礎のまとめ
| SOPH 基礎統計学 | |
|---|---|
| 時価総額 | US$648.67m |
| 収益（TTM） | -US$80.88m |
| 売上高(TTM) | US$86.17m |
8.2x
P/Sレシオ-8.7x
PER（株価収益率SOPH は割高か？
公正価値と評価分析を参照収益と収入
| SOPH 損益計算書（TTM） | |
|---|---|
| 収益 | US$86.17m |
| 売上原価 | US$28.76m |
| 売上総利益 | US$57.41m |
| その他の費用 | US$138.29m |
| 収益 | -US$80.88m |
直近の収益報告
Jun 30, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -0.95 |
| グロス・マージン | 66.63% |
| 純利益率 | -93.86% |
| 有利子負債／自己資本比率 | 57.7% |
SOPH の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/08/19 23:31 |
| 終値 | 2026/08/19 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
SOPHiA GENETICS SA 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7
| アナリスト | 機関 |
|---|---|
| Mark Massaro | BTIG |
| William Bonello | Craig-Hallum Capital Group LLC |
| Subhalaxmi Nambi | Guggenheim Securities, LLC |